<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NPG//DTD XML Article//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName NPG_XML_Article.dtd?>
<?SourceDTD.Version 2.7.10?>
<?ConverterInfo.XSLTName nature2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
    <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
    <journal-title-group>
      <journal-title>Scientific Reports</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2045-2322</issn>
    <publisher>
      <publisher-name>Nature Publishing Group</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">4980628</article-id>
    <article-id pub-id-type="pii">srep31128</article-id>
    <article-id pub-id-type="doi">10.1038/srep31128</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>VHLdb: A database of von Hippel-Lindau protein interactors and mutations</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Tabaro</surname>
          <given-names>Francesco</given-names>
        </name>
        <xref ref-type="aff" rid="a1">1</xref>
        <xref ref-type="aff" rid="a2">2</xref>
        <xref ref-type="author-notes" rid="n1">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Minervini</surname>
          <given-names>Giovanni</given-names>
        </name>
        <xref ref-type="aff" rid="a1">1</xref>
        <xref ref-type="author-notes" rid="n1">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sundus</surname>
          <given-names>Faiza</given-names>
        </name>
        <xref ref-type="aff" rid="a1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Quaglia</surname>
          <given-names>Federica</given-names>
        </name>
        <xref ref-type="aff" rid="a1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Leonardi</surname>
          <given-names>Emanuela</given-names>
        </name>
        <xref ref-type="aff" rid="a3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Piovesan</surname>
          <given-names>Damiano</given-names>
        </name>
        <xref ref-type="aff" rid="a1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tosatto</surname>
          <given-names>Silvio C. E.</given-names>
        </name>
        <xref ref-type="corresp" rid="c1">a</xref>
        <xref ref-type="aff" rid="a1">1</xref>
        <xref ref-type="aff" rid="a4">4</xref>
      </contrib>
      <aff id="a1"><label>1</label><institution>Department of Biomedical Sciences and CRIBI Biotechnology
Center, University of Padova</institution>, Viale G. Colombo 3,
35121, Padova, <country>Italy</country></aff>
      <aff id="a2"><label>2</label><institution>Institute of Biosciences and Medical Technology</institution>,
Tampere, <country>Finland</country></aff>
      <aff id="a3"><label>3</label><institution>Department of Woman and Child Health, University of Padua</institution>,
35131
Padua, <country>Italy</country></aff>
      <aff id="a4"><label>4</label><institution>CNR Institute of Neuroscience</institution>, Padova,
<country>Italy</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="c1">
        <label>a</label>
        <email>silvio.tosatto@unipd.it</email>
      </corresp>
      <fn id="n1">
        <label>*</label>
        <p>These authors contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>11</day>
      <month>08</month>
      <year>2016</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2016</year>
    </pub-date>
    <volume>6</volume>
    <elocation-id>31128</elocation-id>
    <history>
      <date date-type="received">
        <day>14</day>
        <month>05</month>
        <year>2016</year>
      </date>
      <date date-type="accepted">
        <day>08</day>
        <month>07</month>
        <year>2016</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2016, The Author(s)</copyright-statement>
      <copyright-year>2016</copyright-year>
      <copyright-holder>The Author(s)</copyright-holder>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <!--author-paid-->
        <license-p>This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative
Commons license, users will need to obtain permission from the license holder to
reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
      </license>
    </permissions>
    <abstract>
      <p>Mutations in von Hippel-Lindau tumor suppressor protein (pVHL) predispose to develop
tumors affecting specific target organs, such as the retina, epididymis, adrenal
glands, pancreas and kidneys. Currently, more than 400 pVHL interacting
proteins are either described in the literature or predicted in public databases.
This data is scattered among several different sources, slowing down the
comprehension of pVHL’s biological role. Here we present VHLdb, a novel
database collecting available interaction and mutation data on pVHL to provide novel
integrated annotations. In VHLdb, pVHL interactors are organized according to two
annotation levels, manual and automatic. Mutation data are easily accessible and a
novel visualization tool has been implemented. A user-friendly feedback function to
improve database content through community-driven curation is also provided. VHLdb
presently contains 478 interactors, of which 117 have been manually curated, and
1,074 mutations. This makes it the largest available database for pVHL-related
information. VHLdb is available from URL: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://vhldb.bio.unipd.it/">http://vhldb.bio.unipd.it/</ext-link>.</p>
    </abstract>
  </article-meta>
</front>
<body>
  <p>Von Hippel-Lindau (VHL) syndrome is a hereditary predisposition to develop several
cancers resulting from pathological inactivation of the von Hippel-Lindau protein
(pVHL)<xref ref-type="bibr" rid="b1">1</xref><xref ref-type="bibr" rid="b2">2</xref><xref ref-type="bibr" rid="b3">3</xref>. pVHL is the product of the same gene located on
chromosome 3p25 and constantly transcribed in both fetal and adult tissues<xref ref-type="bibr" rid="b4">4</xref>. Two different alternatively-spliced isoforms were initially identified<xref ref-type="bibr" rid="b5">5</xref>. pVHL30 contains all 213 residues of the VHL gene, whereas pVHL19 lacks the first 53
residues due to an alternative translation start site<xref ref-type="bibr" rid="b5">5</xref>. Both isoforms are
biologically active, binding elongins B and C and cullin 2 to form an ubiquitin E3
ligase complex known as VCB<xref ref-type="bibr" rid="b6">6</xref><xref ref-type="bibr" rid="b7">7</xref>. The main pVHL function is
ubiquitin-mediated degradation of hypoxia-inducible factor 1-alpha
(HIF-1α)<xref ref-type="bibr" rid="b3">3</xref> and pVHL activity is crucial in the oxygen
sensing pathway. Under physiological oxygen concentrations, pVHL targets
HIF-1α for proteosomal degradation. In hypoxic conditions HIF-1α
escapes ubiquitin-mediated proteolysis and translocates to the nucleus, where it
activates many genes involved in angiogenesis, oxidative metabolism, cell survival, and
cancer progression<xref ref-type="bibr" rid="b3">3</xref><xref ref-type="bibr" rid="b8">8</xref>. Several other cellular functions not directly
related to the pVHL/HIF-1α axis are also reported<xref ref-type="bibr" rid="b9">9</xref><xref ref-type="bibr" rid="b10">10</xref><xref ref-type="bibr" rid="b11">11</xref><xref ref-type="bibr" rid="b12">12</xref><xref ref-type="bibr" rid="b13">13</xref><xref ref-type="bibr" rid="b14">14</xref><xref ref-type="bibr" rid="b15">15</xref>, e.g. external matrix deposition, drawing a
complex scenario for pVHL in cells and tissues. Numerous efforts addressed the specific
pVHL molecular pathway<xref ref-type="bibr" rid="b16">16</xref><xref ref-type="bibr" rid="b17">17</xref>, describing pVHL as a molecular hub,
mediating interactions with more than 200 different proteins<xref ref-type="bibr" rid="b18">18</xref>. Recently,
a third pVHL isoform of unknown function was reported in the literature<xref ref-type="bibr" rid="b19">19</xref>, making an interpretation of pVHL’s molecular role even harder. pVHL has
no significant sequence identity to other human proteins, but is well conserved within
mammals<xref ref-type="bibr" rid="b20">20</xref>. Even between mammals pVHL shows important differences. The
main distinction resides in the N-terminus of pVHL30, which is disordered<xref ref-type="bibr" rid="b21">21</xref> and contains many copies of an acidic pentamer in human and other higher primates,
while being shorter and lacking the disordered N-terminal tail region in lower
mammals<xref ref-type="bibr" rid="b22">22</xref>. VHL syndrome is characterized by the development of
several generally benign tumors, which affect specific target organs, such as the
retina, epididymis, adrenal glands, pancreas and kidneys<xref ref-type="bibr" rid="b1">1</xref><xref ref-type="bibr" rid="b23">23</xref><xref ref-type="bibr" rid="b24">24</xref>. It is
considered a severe autosomal dominant genetic condition with inheritance of one in over
35,000<xref ref-type="bibr" rid="b25">25</xref>. Defects of pVHL function are not limited to the sole VHL
syndrome. It is thought that pVHL tumor suppressor loss of function is present in ca.
75% of clear cell renal cellular carcinomas (ccRCC) not directly related to VHL
syndrome<xref ref-type="bibr" rid="b26">26</xref>. Recent studies also suggest a role for pVHL in p53 tumor
suppressor regulation<xref ref-type="bibr" rid="b27">27</xref><xref ref-type="bibr" rid="b28">28</xref>. Kidney-specific pVHL inactivation causes the
development of kidney cysts in a mouse model<xref ref-type="bibr" rid="b29">29</xref>, while reintroduction of a
wild type gene interrupts malignant progression<xref ref-type="bibr" rid="b30">30</xref>. A number of
experimental and <italic>in silico</italic> data of proteins involved in pVHL tumorigenesis is
reported<xref ref-type="bibr" rid="b9">9</xref><xref ref-type="bibr" rid="b13">13</xref> and contained in large databases, such as IntAct<xref ref-type="bibr" rid="b18">18</xref>, STRING<xref ref-type="bibr" rid="b31">31</xref> and BioGRID<xref ref-type="bibr" rid="b32">32</xref>. It is thought
that pVHL has at least four different protein-protein interaction interfaces (A to
D)<xref ref-type="bibr" rid="b13">13</xref>. Several specific interactors were found for each interface and
correlation with functions other than oxygen sensing, such as DNA-damage repair<xref ref-type="bibr" rid="b33">33</xref>, microtubule dynamics<xref ref-type="bibr" rid="b34">34</xref> and oxidative metabolism,
reinforce the pivotal role of pVHL. As the amount of details known about pVHL function
is rapidly increasing, the multiple pVHL roles may confound our understanding of this
complex protein. Knowledge is usually derived from freely accessible protein sequence
and function databases. Although valuable, these universal resources are generalist by
design, yielding a strong fragmentation of the huge amount of pVHL data. For a
non-bioinformatician, scattered information represents one of the biggest hurdles,
slowing down a holistic understanding of the pVHL biological role. Here we present
VHLdb, a novel resource providing expert curation for the pVHL tumor suppressor. The
database was primarily designed to be effective for a non-expert, making information
retrieval easier. Overall, VHLdb accounts for 478 unique interactors in two curation
levels (manual and automatic), with data retrieved from different sources. Detailed
information on the pVHL interaction interface and post-translational modifications were
also included. A feedback function allows inclusion of novel information from experts in
the field wishing to contribute annotation on interactors or mutations. Finally, a
downloading tool is also provided for data sharing.</p>
  <sec disp-level="1">
    <title>Database Description</title>
    <sec disp-level="2">
      <title>Mutation data</title>
      <p>Germline and somatic mutations have been collected from<xref ref-type="bibr" rid="b35">35</xref><xref ref-type="bibr" rid="b36">36</xref><xref ref-type="bibr" rid="b37">37</xref><xref ref-type="bibr" rid="b38">38</xref>, integrated<xref ref-type="bibr" rid="b39">39</xref><xref ref-type="bibr" rid="b40">40</xref><xref ref-type="bibr" rid="b41">41</xref> and annotated
with predictions on protein stability. The final dataset is made up of 1,074
mutations and, to the best of our knowledge, represents the largest publicly
available repository of pathogenic pVHL variants. An example of mutation details
is given in <xref ref-type="table" rid="t1">Table 1</xref> and <xref ref-type="fig" rid="f1">Fig. 1</xref>.
Where possible, a pVHL interacting surface has been defined for each mutation.
E.g. frameshift mutations cannot be assigned to any surface due to their
intrinsic nature. Solvent accessibility has been computed for each mutation
using DSSP<xref ref-type="bibr" rid="b42">42</xref> and mutated residues are defined exposed when at
least 20% of their surface is accessible to solvent. Bluues<xref ref-type="bibr" rid="b43">43</xref> and
NeEMO<xref ref-type="bibr" rid="b44">44</xref> have been run on all possible mutations, using the
pVHL 3D structure with PDB code 1LM8 as reference. Current pVHL 3D structures
cover only the structured part of the protein (i.e. alpha- and beta-domains),
lacking the first 60 residues which form an intrinsically disordered tail.
Pathogenicity assessment for mutations in this segment was not included in VHLdb
to avoid the risk of erroneous interpretation from low confidence predictions.
Bluues<xref ref-type="bibr" rid="b43">43</xref> calculates the electrostatic properties of a protein
and is able to predict electrostatic properties of mutated solvent exposed
residues. NeEMO<xref ref-type="bibr" rid="b44">44</xref> evaluates stability changes caused by amino
acid substitutions using a machine learning based approach from structure. It
has been run on all point mutations of the crystallized protein, i.e. again
excluding only the N-terminus.</p>
    </sec>
    <sec disp-level="2">
      <title>pVHL interactome</title>
      <p>The pVHL interactome has been defined starting from searches in publicly
available databases. VHLdb contains two levels of annotation for interactors,
automatic and manual (<xref ref-type="fig" rid="f2">Fig. 2</xref>). Automatic annotations are
denoted by an empty silver star and build the overall pVHL interactome, albeit
at a lower confidence level. Manually curated pVHL interactors, represented with
a a gold star, have been annotated with the exact molecular details and their
functional meaning.</p>
      <p>The automatic pVHL interaction network has been generated with queries to the
STRING<xref ref-type="bibr" rid="b31">31</xref>, BioGrid<xref ref-type="bibr" rid="b45">45</xref>, iHOP<xref ref-type="bibr" rid="b46">46</xref>,
MIPS<xref ref-type="bibr" rid="b47">47</xref> and IMEx<xref ref-type="bibr" rid="b48">48</xref> databases. STRING and
Biogrid are two of the most popular protein-protein interaction databases. The
IMEx Consortium is a long-term coordination project which currently contains
twelve interaction databases. MIPS is a database of mammalian interacting
proteins while iHOPS is a text-mining based resource parsing the PubMed database
for possible statements on a target protein interaction. Both are presented in a
human readable format and their data is not associated with a confidence score.
All interactions from IMEx, STRING are annotated with this measurement, while
BioGrid interactions are poorly annotated. When available, this score is
reported in the interactor page so the user can easily assess the interaction
quality. The five resources have been queried through the standard user
interface using the most general terms, i.e. “VHL” or
“pVHL”. In all cases, only human interaction data was
considered. The results from the different sources have been merged and
processed to remove duplicates. Annotation from UniProt<xref ref-type="bibr" rid="b49">49</xref>,
PDB<xref ref-type="bibr" rid="b50">50</xref>, Gene Ontology<xref ref-type="bibr" rid="b51">51</xref>, Pfam<xref ref-type="bibr" rid="b52">52</xref>
and MobiDB<xref ref-type="bibr" rid="b21">21</xref> has been added. Searches in interaction databases
allowed us to build the full network, currently containing 478 proteins.</p>
    </sec>
    <sec disp-level="2">
      <title>Manually curated pVHL interactions</title>
      <p>The manually curated high quality pVHL interaction network is currently composed
of 117 proteins. 35 come from a previous publication<xref ref-type="bibr" rid="b13">13</xref> while the
others have been annotated and are presented in this work (see <xref ref-type="table" rid="t2">Table 2</xref>). Data curation was performed by each expert following an
in-house standardized protocol to guarantee reproducibility and correctness. In
detail, the manual curation workflow considers a preliminary search in
Pubmed<xref ref-type="bibr" rid="b53">53</xref> and Uniprot<xref ref-type="bibr" rid="b49">49</xref> using pVHL-related
keywords (e.g. “VHL syndrome”, “pVHL AND
ccRCC”) adapted to the interactor under investigation. Keywords were
manually selected by curators using the most common keywords found in the VHL
syndrome literature, e.g. angiogenesis, proteasome degradation, oxygen sensing.
In case of proteins with different synonymous names (e.g. the EGLN protein
family also known as PHD) multiple searches were performed. The final
nomenclature for each VHLdb entry was chosen using the official HGNC consortium
name. Interaction details have been manually extracted from the literature.
Pubmed has been searched for papers describing either structural details of the
interaction (e.g. pVHL and target protein residues, sequence motifs and domains)
and their functional implications. An example of structural details of the
interaction is given in <xref ref-type="fig" rid="f3">Fig. 3</xref>. Upon identification, each
interactor has been analyzed with Consurf <xref ref-type="bibr" rid="b54">54</xref> to
assess sequence conservation as well as PRISM<xref ref-type="bibr" rid="b55">55</xref> and
Crescendo<xref ref-type="bibr" rid="b56">56</xref> to predict the spatial localization of the
interaction at the residue level. Presence of linear sequence motifs, known to
be relevant in protein-protein interactions, post-translational modification or
enzymatic cleavage was performed with ELM<xref ref-type="bibr" rid="b57">57</xref>. The interaction
surface was assigned following our classification<xref ref-type="bibr" rid="b13">13</xref> as summarized
in <xref ref-type="table" rid="t3">Table 3</xref>.</p>
    </sec>
    <sec disp-level="2">
      <title>Implementation</title>
      <p>VHLdb uses separate modules for data management, processing and presentation.
<xref ref-type="fig" rid="f4">Figure 4</xref> shows a schematic representation of the whole
application. To eliminate the need for data conversion, simplifying development
and maintenance, all modules share the JSON (JavaScript Object Notation) format
to exchange data. The MongoDB database engine is used for storage and Node.js as
middleware between data and presentation. VHLdb exposes its resources through a
RESTful interface, using the Restify library for Node.js. At the time of
writing, VHLdb supports a custom REST API, the search-route, as detailed in the
Help page. The user interface is implemented using the Angular.js framework and
Bootstrap library. These libraries provide a mobile-ready interface, allowing
VHLdb to be natively accessed from any kind of device. Structural annotations
are displayed with the Web-GL based molecular viewer PV<xref ref-type="bibr" rid="b58">58</xref>. Custom
molecular views have been developed. An “interaction
viewer” has been implemented in the entry page to display
interaction data and a “mutation viewer” has been
implemented in the mutations page. The former allows the user to visualize the
pVHL residues interacting with a manually curated interacting protein by
highlighting the interacting region on the pVHL structure. The latter displays
the location of any mutation on the pVHL structure as a sphere, allowing the
user to visually access the structural location of a mutation. VHLdb allows
direct download of all pVHL interactions, as well as mutations. The database
offers both a graphical web interface and RESTful web services from the URL:
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://VHLdb.bio.unipd.it/">http://VHLdb.bio.unipd.it/</ext-link>.</p>
    </sec>
  </sec>
  <sec disp-level="1">
    <title>Results</title>
    <sec disp-level="2">
      <title>Using VHLdb</title>
      <p>VHLdb offers simple yet powerful ways to access its data. First, the navigation
bar on top of the home page allows the user to access the mutation or
interaction page. The home page features a clickable map, redirecting the user
to interface-specific pVHL interaction lists (<xref ref-type="fig" rid="f2">Fig. 2</xref>). The
mutation page lists all coding variants (sorted by codon) in a user-friendly
searchable, filterable and downloadable table, as well as the previously
described mutation viewer. The interaction page features a graphical
representation of the manually curated pVHL interaction network organized by
interacting surface and a sortable, searchable and filterable table, similar to
the mutations one listing all protein-protein interactions. The third element of
this page is a table showing Gene Ontology (GO) enrichment analysis results for
each surface and GO tree. This page allows download of the complete pVHL
interaction set in four different formats (JSON, XML, CSV and TAB separated).
Details of any protein can be accessed from the interaction page. This page
shows all available annotations for a particular pVHL interacting protein
including general annotations from UniProt, manually curated interaction details
(if available), sequence annotation from Pfam and MobiDB, structure annotations
from PDB, functional annotation from GO and references from PubMed. All these
data can be downloaded in a protein-specific way in the formats specified above.
A feeedback form is accessible from this page and can be used to report
inconsistencies or suggest annotations for a specific pVHL interacting protein.
Another way to give feedback and request data submission is the contact page
accessible from the navigation bar, featuring two distinct submission forms, for
general feedback and specific data submission requests. These messages are
manually reviewed by our curators and after validation, i.e. confirmation of
user-suggested literature, the proposed data will be added to VHLdb.</p>
    </sec>
    <sec disp-level="2">
      <title>VHLdb statistics</title>
      <p>VHLdb collects data on 478 pVHL interacting proteins and 1,074 pathogenic somatic
or germline pVHL mutations. In total, 117 of 478 pVHL interacting proteins were
manually reviewed and constitute the core curated pVHL interaction network. The
remaining proteins constitute the automated low confidence pVHL interaction
network. For 62 proteins of the core set it was possible to identify the
interacting surface (see <xref ref-type="table" rid="t3">Table 3</xref>). For 55 proteins it
was possible to identify the pVHL residues involved in the interaction, and for
10 the residues of the interaction partner as well. For 51 proteins we also
defined whether the interaction between pVHL and any other protein is direct or
not. <xref ref-type="table" rid="t2">Table 2</xref> shows a more detailed listing of the
manually curated VHLdb protein set. Statistical analysis shows that the
interactor distribution differs among the four pVHL interfaces. Interface A
presents 9 exclusive interactors, distributed between sub-interfaces A1 and A2,
and is known to bind elongins B and C and cullin 2 to form the VCB complex<xref ref-type="bibr" rid="b6">6</xref>. Interacting proteins in this region compete with elongins B and
C, highlighting pVHL functions beyond the well known HIF-1α
degradation. We also found that 190 mutations affect this area, yielding three
different VHL phenotypes. E.g. Guanine nucleotide-binding protein subunit
beta-2-like 1 and E2F transcription factor 1 (UniProt codes: P63244 and Q01094,
respectively) are both known to promote cell cycle progression under different
stimuli. A simple database search shows that the two proteins rely on the same
interaction interface, suggesting a correlated role, at least for pVHL binding.
Their interaction with the same pVHL surface suggests a pivotal pVHL role in
controlling cell cycle progression under different stimuli and oxygen
concentrations. Similar results were found for the remaining interaction
interfaces. In detail, 39 interactors were found for interface B, 6 for
interface C and one interactor for interface D, for a total of 827 different
mutations distributed among interaction interfaces. Interface B is the
HIF-1α binding region and characterized by the largest number of
interactors. As a further example, we found that proteins such as tubulin beta,
collagen alpha-1(IV) and kinesin bind sub-interface B2 showing that molecular
details of functions related to endothelial matrix regulation<xref ref-type="bibr" rid="b15">15</xref>
should correspond to this specific interaction area.</p>
    </sec>
  </sec>
  <sec disp-level="1">
    <title>Conclusions</title>
    <p>We have presented VHLdb, a novel database collecting curated information on pVHL
interactors and mutation effects. It provides comprehensive information of pVHL
interactors derived from different sources as a unique structured resource. As
detailed information about VHL disease is rapidly increasing, this huge amount of
information is scattered in different generalist resources and not promptly
reachable by a non-expert user. We expect the VHLdb to be useful for both
experimentalists seeking to study pVHL biology in greater details and clinicians
aiming to understand the effects of novel pVHL variants. An intuitive pVHL oriented
user interface was designed and four different output formats are provided to
facilitate data retrieval. VHLdb is also effective for the qualitative study of pVHL
pathogenic mutations and interacting proteins. From a total of 478 different
interactors, 62 were mapped on the corresponding interaction interface. Moreover,
1,074 somatic and germline pathogenic mutations are reported, increasing the
previous set of pathogenic pVHL mutations<xref ref-type="bibr" rid="b35">35</xref>. This can be particularly
helpful for future mutation-correlation studies. Information in VHLdb may serve the
scientific community to decipher data derived from tumor genome sequencing
projects<xref ref-type="bibr" rid="b59">59</xref> as well as to provide high quality data to be included
in predictive genomics studies<xref ref-type="bibr" rid="b60">60</xref>. Updates such as error reports and
submissions of new data to VHLdb are highly encouraged from the community through
the implemented feedback function. For the future, it is envisaged the VHLdb will
include more annotations, such as distinct causal relationships between mutations
and affected pathways.</p>
  </sec>
  <sec disp-level="1">
    <title>Additional Information</title>
    <p><bold>How to cite this article</bold>: Tabaro, F. <italic>et al.</italic> VHLdb: A database of von
Hippel-Lindau protein interactors and mutations. <italic>Sci. Rep.</italic>
<bold>6</bold>, 31128; doi: 10.1038/srep31128 (2016).</p>
  </sec>
</body>
<back>
  <ack>
    <p>This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC)
grant MFAG12740 and IG17753 to ST. FT and DP are AIRC research fellows. The funders
had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript. The authors are grateful to Chiara Sartor for initial
help with the dataset and to members of the BioComputingUP group for insightful
discussions.</p>
  </ack>
  <ref-list>
    <ref id="b1">
      <mixed-citation publication-type="journal"><name><surname>Gnarra</surname><given-names>J. R.</given-names></name><italic>et al.</italic><article-title>Mutations of the VHL tumour suppressor gene in renal carcinoma</article-title>.
<source>Nat. Genet.</source><volume>7</volume>, <fpage>85</fpage>–<lpage>90</lpage> (<year>1994</year>).<pub-id pub-id-type="pmid">7915601</pub-id></mixed-citation>
    </ref>
    <ref id="b2">
      <mixed-citation publication-type="journal"><name><surname>Gossage</surname><given-names>L.</given-names></name>, <name><surname>Eisen</surname><given-names>T.</given-names></name> &amp; <name><surname>Maher</surname><given-names>E.
R.</given-names></name>
<article-title>VHL, the story of a tumour suppressor gene</article-title>. <source>Nat Rev Cancer</source>
<volume>15</volume>, <fpage>55</fpage>–<lpage>64</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25533676</pub-id></mixed-citation>
    </ref>
    <ref id="b3">
      <mixed-citation publication-type="journal"><name><surname>Hon</surname><given-names>W.-C.</given-names></name><italic>et al.</italic><article-title>Structural basis for the recognition of hydroxyproline in HIF-1 alpha by
pVHL</article-title>. <source>Nature</source><volume>417</volume>, <fpage>975</fpage>–<lpage>978</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12050673</pub-id></mixed-citation>
    </ref>
    <ref id="b4">
      <mixed-citation publication-type="journal"><name><surname>Stolle</surname><given-names>C.</given-names></name><italic>et al.</italic><article-title>Improved detection of germline mutations in the von Hippel-Lindau disease
tumor suppressor gene</article-title>. <source>Hum. Mutat.</source><volume>12</volume>, <fpage>417</fpage>–<lpage>423</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9829911</pub-id></mixed-citation>
    </ref>
    <ref id="b5">
      <mixed-citation publication-type="journal"><name><surname>Richards</surname><given-names>F. M.</given-names></name>,
<name><surname>Schofield</surname><given-names>P. N.</given-names></name>,
<name><surname>Fleming</surname><given-names>S.</given-names></name> &amp;
<name><surname>Maher</surname><given-names>E. R.</given-names></name>
<article-title>Expression of the von Hippel-Lindau disease tumour suppressor gene during
human embryogenesis</article-title>. <source>Hum. Mol. Genet.</source>
<volume>5</volume>, <fpage>639</fpage>–<lpage>644</lpage> (<year>1996</year>).<pub-id pub-id-type="pmid">8733131</pub-id></mixed-citation>
    </ref>
    <ref id="b6">
      <mixed-citation publication-type="journal"><name><surname>Kibel</surname><given-names>A.</given-names></name>,
<name><surname>Iliopoulos</surname><given-names>O.</given-names></name>,
<name><surname>DeCaprio</surname><given-names>J. A.</given-names></name> &amp;
<name><surname>Kaelin</surname><given-names>W. G.</given-names></name>
<article-title>Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and
C</article-title>. <source>Science</source>
<volume>269</volume>, <fpage>1444</fpage>–<lpage>1446</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7660130</pub-id></mixed-citation>
    </ref>
    <ref id="b7">
      <mixed-citation publication-type="journal"><name><surname>Iwai</surname><given-names>K.</given-names></name><italic>et al.</italic><article-title>Identification of the von Hippel-lindau tumor-suppressor protein as part of
an active E3 ubiquitin ligase complex</article-title>. <source>Proc. Natl. Acad. Sci.
USA</source><volume>96</volume>, <fpage>12436</fpage>–<lpage>12441</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10535940</pub-id></mixed-citation>
    </ref>
    <ref id="b8">
      <mixed-citation publication-type="journal"><name><surname>Ivan</surname><given-names>M.</given-names></name><italic>et al.</italic><article-title>HIFalpha targeted for VHL-mediated destruction by proline hydroxylation:
implications for O2 sensing</article-title>. <source>Science</source><volume>292</volume>, <fpage>464</fpage>–<lpage>468</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11292862</pub-id></mixed-citation>
    </ref>
    <ref id="b9">
      <mixed-citation publication-type="journal"><name><surname>Frew</surname><given-names>I. J.</given-names></name> &amp;
<name><surname>Krek</surname><given-names>W.</given-names></name>
<article-title>pVHL: a multipurpose adaptor protein</article-title>. <source>Sci Signal</source>
<volume>1</volume>, <fpage>pe30</fpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18560019</pub-id></mixed-citation>
    </ref>
    <ref id="b10">
      <mixed-citation publication-type="journal"><name><surname>Gamper</surname><given-names>A. M.</given-names></name><italic>et al.</italic><article-title>Regulation of KLF4 Turnover Reveals an Unexpected Tissue-Specific Role of
pVHL in Tumorigenesis</article-title>. <source>Molecular Cell</source><volume>45</volume>, <fpage>233</fpage>–<lpage>243</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22284679</pub-id></mixed-citation>
    </ref>
    <ref id="b11">
      <mixed-citation publication-type="journal"><name><surname>Du</surname><given-names>J.</given-names></name><italic>et al.</italic><article-title>pVHL Negatively Regulates Antiviral Signaling by Targeting MAVS for
Proteasomal Degradation</article-title>. <source>J Immunol</source><fpage>1500588</fpage> doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1500588</pub-id> (<year>2015</year>).</mixed-citation>
    </ref>
    <ref id="b12">
      <mixed-citation publication-type="journal"><name><surname>Xue</surname><given-names>J.</given-names></name><italic>et al.</italic><article-title>pVHL Mediates K63-Linked Ubiquitination of nCLU</article-title>. <source>PLoS ONE</source><volume>7</volume>, <fpage>e35848</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22532874</pub-id></mixed-citation>
    </ref>
    <ref id="b13">
      <mixed-citation publication-type="journal"><name><surname>Leonardi</surname><given-names>E.</given-names></name>, <name><surname>Murgia</surname><given-names>a</given-names></name> &amp; <name><surname>Tosatto</surname><given-names>S. C.
E.</given-names></name>
<article-title>Adding structural information to the von Hippel-Lindau (VHL) tumor
suppressor interaction network</article-title>. <source>FEBS letters</source>
<volume>583</volume>, <fpage>3704</fpage>–<lpage>3710</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19878677</pub-id></mixed-citation>
    </ref>
    <ref id="b14">
      <mixed-citation publication-type="journal"><name><surname>Ohh</surname><given-names>M.</given-names></name><italic>et al.</italic><article-title>The von Hippel-Lindau tumor suppressor protein is required for proper
assembly of an extracellular fibronectin matrix</article-title>. <source>Mol. Cell</source><volume>1</volume>, <fpage>959</fpage>–<lpage>968</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9651579</pub-id></mixed-citation>
    </ref>
    <ref id="b15">
      <mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>N.</given-names></name>, <name><surname>Mack</surname><given-names>F.</given-names></name> &amp; <name><surname>Haase</surname><given-names>V.</given-names></name>
<article-title>pVHL function is essential for endothelial extracellular matrix
deposition.</article-title>
<source>Molecular and cellular \ldots</source>
<volume>26</volume>, (<year>2006</year>).</mixed-citation>
    </ref>
    <ref id="b16">
      <mixed-citation publication-type="journal"><name><surname>Lai</surname><given-names>Y.</given-names></name>, <name><surname>Song</surname><given-names>M.</given-names></name>, <name><surname>Hakala</surname><given-names>K.</given-names></name>,
<name><surname>Weintraub</surname><given-names>S. T.</given-names></name> &amp;
<name><surname>Shiio</surname><given-names>Y.</given-names></name>
<article-title>Proteomic dissection of the von Hippel-Lindau (VHL) interactome</article-title>.
<source>J. Proteome Res.</source>
<volume>10</volume>, <fpage>5175</fpage>–<lpage>5182</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21942715</pub-id></mixed-citation>
    </ref>
    <ref id="b17">
      <mixed-citation publication-type="journal"><name><surname>Minervini</surname><given-names>G.</given-names></name><italic>et al.</italic><article-title>Design and analysis of a Petri net model of the Von Hippel-Lindau (VHL)
tumor suppressor interaction network</article-title>. <source>PLoS ONE</source><volume>9</volume>, <fpage>e96986</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24886840</pub-id></mixed-citation>
    </ref>
    <ref id="b18">
      <mixed-citation publication-type="journal"><name><surname>Kerrien</surname><given-names>S.</given-names></name><italic>et al.</italic><article-title>The IntAct molecular interaction database in 2012</article-title>. <source>Nucleic Acids
Res.</source><volume>40</volume>, <fpage>D841</fpage>–<lpage>D846</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22121220</pub-id></mixed-citation>
    </ref>
    <ref id="b19">
      <mixed-citation publication-type="journal"><name><surname>Chesnel</surname><given-names>F.</given-names></name><italic>et al.</italic><article-title>The von Hippel–Lindau tumour suppressor gene: uncovering the
expression of the pVHL172 isoform</article-title>. <source>Br J Cancer</source> doi:
<pub-id pub-id-type="doi">10.1038/bjc.2015.189</pub-id> (<year>2015</year>).</mixed-citation>
    </ref>
    <ref id="b20">
      <mixed-citation publication-type="journal"><name><surname>Woodward</surname><given-names>E. R.</given-names></name><italic>et al.</italic><article-title>Comparative sequence analysis of the VHL tumor suppressor gene</article-title>.
<source>Genomics</source><volume>65</volume>, <fpage>253</fpage>–<lpage>265</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10857749</pub-id></mixed-citation>
    </ref>
    <ref id="b21">
      <mixed-citation publication-type="journal"><name><surname>Potenza</surname><given-names>E.</given-names></name>, <name><surname>Di
Domenico</surname><given-names>T.</given-names></name>, <name><surname>Walsh</surname><given-names>I.</given-names></name> &amp; <name><surname>Tosatto</surname><given-names>S. C.
E.</given-names></name>
<article-title>MobiDB 2.0: an improved database of intrinsically disordered and mobile
proteins</article-title>. <source>Nucleic Acids Res.</source>
<volume>43</volume>, <fpage>D315</fpage>–<lpage>D320</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25361972</pub-id></mixed-citation>
    </ref>
    <ref id="b22">
      <mixed-citation publication-type="journal"><name><surname>Minervini</surname><given-names>G.</given-names></name><italic>et al.</italic><article-title>Isoform-specific interactions of the von Hippel-Lindau tumor suppressor
protein</article-title>. <source>Sci Rep</source><volume>5</volume>, <fpage>12605</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26211615</pub-id></mixed-citation>
    </ref>
    <ref id="b23">
      <mixed-citation publication-type="journal"><name><surname>Latif</surname><given-names>F.</given-names></name><italic>et al.</italic><article-title>Identification of the von Hippel-Lindau disease tumor suppressor
gene</article-title>. <source>Science</source><volume>260</volume>, <fpage>1317</fpage>–<lpage>1320</lpage> (<year>1993</year>).<pub-id pub-id-type="pmid">8493574</pub-id></mixed-citation>
    </ref>
    <ref id="b24">
      <mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>H.-C. J.</given-names></name><italic>et al.</italic><article-title>Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic
manifestations by inactivating Vhl in specific pancreatic cell
populations</article-title>. <source>PLoS ONE</source><volume>4</volume>, <fpage>e4897</fpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19340311</pub-id></mixed-citation>
    </ref>
    <ref id="b25">
      <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>W. Y.</given-names></name> &amp;
<name><surname>Kaelin</surname><given-names>W. G.</given-names></name>
<article-title>Role of VHL gene mutation in human cancer</article-title>. <source>J. Clin. Oncol.</source>
<volume>22</volume>, <fpage>4991</fpage>–<lpage>5004</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15611513</pub-id></mixed-citation>
    </ref>
    <ref id="b26">
      <mixed-citation publication-type="journal"><name><surname>Young</surname><given-names>A. C.</given-names></name><italic>et al.</italic><article-title>Analysis of VHL Gene Alterations and their Relationship to Clinical
Parameters in Sporadic Conventional Renal Cell Carcinoma</article-title>. <source>Clin.
Cancer Res.</source><volume>15</volume>, <fpage>7582</fpage>–<lpage>7592</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19996202</pub-id></mixed-citation>
    </ref>
    <ref id="b27">
      <mixed-citation publication-type="journal"><name><surname>Fels</surname><given-names>D. R.</given-names></name> &amp;
<name><surname>Koumenis</surname><given-names>C.</given-names></name>
<article-title>HIF-1alpha and p53: the ODD couple?</article-title>
<source>Trends Biochem. Sci.</source>
<volume>30</volume>, <fpage>426</fpage>–<lpage>429</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15996866</pub-id></mixed-citation>
    </ref>
    <ref id="b28">
      <mixed-citation publication-type="journal"><name><surname>Jung</surname><given-names>Y.-S.</given-names></name><italic>et al.</italic><article-title>Loss of VHL promotes progerin expression, leading to impaired p14/ARF
function and suppression of p53 activity</article-title>. <source>Cell Cycle</source><volume>12</volume>, <fpage>2277</fpage>–<lpage>2290</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">24067370</pub-id></mixed-citation>
    </ref>
    <ref id="b29">
      <mixed-citation publication-type="journal"><name><surname>Rankin</surname><given-names>E. B.</given-names></name>,
<name><surname>Tomaszewski</surname><given-names>J. E.</given-names></name> &amp;
<name><surname>Haase</surname><given-names>V. H.</given-names></name>
<article-title>Renal cyst development in mice with conditional inactivation of the von
Hippel-Lindau tumor suppressor</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>2576</fpage>–<lpage>2583</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16510575</pub-id></mixed-citation>
    </ref>
    <ref id="b30">
      <mixed-citation publication-type="journal"><name><surname>Iliopoulos</surname><given-names>O.</given-names></name>,
<name><surname>Kibel</surname><given-names>A.</given-names></name>, <name><surname>Gray</surname><given-names>S.</given-names></name> &amp; <name><surname>Kaelin</surname><given-names>W.
G.</given-names></name>
<article-title>Tumour suppression by the human von Hippel-Lindau gene product</article-title>.
<source>Nat Med</source>
<volume>1</volume>, <fpage>822</fpage>–<lpage>826</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7585187</pub-id></mixed-citation>
    </ref>
    <ref id="b31">
      <mixed-citation publication-type="journal"><name><surname>Franceschini</surname><given-names>A.</given-names></name><italic>et al.</italic><article-title>STRING v9.1: protein-protein interaction networks, with increased coverage
and integration</article-title>. <source>Nucleic Acids Res.</source><volume>41</volume>, <fpage>D808</fpage>–<lpage>D815</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23203871</pub-id></mixed-citation>
    </ref>
    <ref id="b32">
      <mixed-citation publication-type="journal"><name><surname>Stark</surname><given-names>C.</given-names></name><italic>et al.</italic><article-title>BioGRID: a general repository for interaction datasets</article-title>. <source>Nucl.
Acids Res</source>. <volume>34</volume>, <fpage>D535</fpage>–<lpage>D539</lpage>
(<year>2006</year>).<pub-id pub-id-type="pmid">16381927</pub-id></mixed-citation>
    </ref>
    <ref id="b33">
      <mixed-citation publication-type="journal"><name><surname>Roe</surname><given-names>J.-S.</given-names></name>, <name><surname>Kim</surname><given-names>H.-R.</given-names></name>, <name><surname>Hwang</surname><given-names>I.-Y.</given-names></name>, <name><surname>Cho</surname><given-names>E.-J.</given-names></name>
&amp; <name><surname>Youn</surname><given-names>H.-D.</given-names></name>
<article-title>von Hippel-Lindau protein promotes Skp2 destabilization on DNA
damage</article-title>. <source>Oncogene</source>
<volume>30</volume>, <fpage>3127</fpage>–<lpage>3138</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21358672</pub-id></mixed-citation>
    </ref>
    <ref id="b34">
      <mixed-citation publication-type="journal"><name><surname>Lolkema</surname><given-names>M. P.</given-names></name><italic>et al.</italic><article-title>The von Hippel-Lindau tumor suppressor protein influences microtubule
dynamics at the cell periphery</article-title>. <source>Exp. Cell Res.</source><volume>301</volume>, <fpage>139</fpage>–<lpage>146</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15530850</pub-id></mixed-citation>
    </ref>
    <ref id="b35">
      <mixed-citation publication-type="journal"><name><surname>Nordstrom-O’Brien</surname><given-names>M.</given-names></name><italic>et al.</italic><article-title>Genetic analysis of von Hippel-Lindau disease</article-title>. <source>Hum. Mutat.</source><volume>31</volume>, <fpage>521</fpage>–<lpage>537</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20151405</pub-id></mixed-citation>
    </ref>
    <ref id="b36">
      <mixed-citation publication-type="journal"><name><surname>Leonardi</surname><given-names>E.</given-names></name>,
<name><surname>Martella</surname><given-names>M.</given-names></name>,
<name><surname>Tosatto</surname><given-names>S. C. E.</given-names></name> &amp;
<name><surname>Murgia</surname><given-names>A.</given-names></name>
<article-title>Identification and in silico analysis of novel von Hippel-Lindau (VHL) gene
variants from a large population</article-title>. <source>Ann. Hum. Genet.</source>
<volume>75</volume>, <fpage>483</fpage>–<lpage>496</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21463266</pub-id></mixed-citation>
    </ref>
    <ref id="b37">
      <mixed-citation publication-type="journal"><name><surname>Rechsteiner</surname><given-names>M. P.</given-names></name><italic>et al.</italic><article-title>VHL gene mutations and their effects on hypoxia inducible factor
HIFα: identification of potential driver and passenger
mutations</article-title>. <source>Cancer Res.</source><volume>71</volume>, <fpage>5500</fpage>–<lpage>5511</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21715564</pub-id></mixed-citation>
    </ref>
    <ref id="b38">
      <mixed-citation publication-type="journal"><name><surname>Forbes</surname><given-names>S. A.</given-names></name><italic>et al.</italic><article-title>COSMIC: exploring the world’s knowledge of somatic mutations in
human cancer</article-title>. <source>Nucleic Acids Res.</source><volume>43</volume>, <fpage>D805</fpage>–<lpage>D811</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25355519</pub-id></mixed-citation>
    </ref>
    <ref id="b39">
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>B.</given-names></name><italic>et al.</italic><article-title>VHL gene mutation analysis of a Chinese family with non- syndromic
pheochromocytomas and patients with apparently sporadic
pheochromocytoma</article-title>. <source>Asian Pac. J. Cancer Prev.</source><volume>16</volume>, <fpage>1977</fpage>–<lpage>1980</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25773797</pub-id></mixed-citation>
    </ref>
    <ref id="b40">
      <mixed-citation publication-type="journal"><name><surname>Arunachal</surname><given-names>G.</given-names></name><italic>et al.</italic><article-title>Molecular Characterization of a Novel Germline VHL Mutation by Extensive In
Silico Analysis in an Indian Family with Von Hippel-Lindau Disease.</article-title><source>Genet Res Int</source><volume>2016</volume>, <fpage>9872594</fpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27069690</pub-id></mixed-citation>
    </ref>
    <ref id="b41">
      <mixed-citation publication-type="journal"><name><surname>Sorrell</surname><given-names>A. D.</given-names></name><italic>et al.</italic><article-title>Clinical and functional properties of novel VHL mutation (X214L) consistent
with Type 2A phenotype and low risk of renal cell carcinoma</article-title>.
<source>Clin. Genet.</source><volume>79</volume>, <fpage>539</fpage>–<lpage>545</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">20560986</pub-id></mixed-citation>
    </ref>
    <ref id="b42">
      <mixed-citation publication-type="journal"><name><surname>Kabsch</surname><given-names>W.</given-names></name> &amp;
<name><surname>Sander</surname><given-names>C.</given-names></name>
<article-title>Dictionary of protein secondary structure: Pattern recognition of
hydrogen-bonded and geometrical features</article-title>. <source>Biopolymers</source>
<volume>22</volume>, <fpage>2577</fpage>–<lpage>2637</lpage> (<year>1983</year>).<pub-id pub-id-type="pmid">6667333</pub-id></mixed-citation>
    </ref>
    <ref id="b43">
      <mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>I.</given-names></name><italic>et al.</italic><article-title>Bluues server: electrostatic properties of wild-type and mutated protein
structures</article-title>. <source>Bioinformatics</source><volume>28</volume>, <fpage>2189</fpage>–<lpage>2190</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22711791</pub-id></mixed-citation>
    </ref>
    <ref id="b44">
      <mixed-citation publication-type="journal"><name><surname>Giollo</surname><given-names>M.</given-names></name>, <name><surname>Martin</surname><given-names>A. J.</given-names></name>, <name><surname>Walsh</surname><given-names>I.</given-names></name>, <name><surname>Ferrari</surname><given-names>C.</given-names></name>
&amp; <name><surname>Tosatto</surname><given-names>S. C.</given-names></name>
<article-title>NeEMO: a method using residue interaction networks to improve prediction of
protein stability upon mutation.</article-title>
<source>BMC Genomics</source>
<volume>15</volume> Suppl 4, <fpage>S7</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25057121</pub-id></mixed-citation>
    </ref>
    <ref id="b45">
      <mixed-citation publication-type="journal"><name><surname>Chatr-Aryamontri</surname><given-names>A.</given-names></name><italic>et al.</italic><article-title>The BioGRID interaction database: 2015 update</article-title>. <source>Nucleic Acids
Res.</source><volume>43</volume>, <fpage>D470</fpage>–<lpage>D478</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25428363</pub-id></mixed-citation>
    </ref>
    <ref id="b46">
      <mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>R.</given-names></name> &amp;
<name><surname>Valencia</surname><given-names>A.</given-names></name>
<article-title>A gene network for navigating the literature</article-title>. <source>Nat. Genet.</source>
<volume>36</volume>, <fpage>664</fpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15226743</pub-id></mixed-citation>
    </ref>
    <ref id="b47">
      <mixed-citation publication-type="journal"><name><surname>Pagel</surname><given-names>P.</given-names></name><italic>et al.</italic><article-title>The MIPS mammalian protein–protein interaction database</article-title>.
<source>Bioinformatics</source><volume>21</volume>, <fpage>832</fpage>–<lpage>834</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15531608</pub-id></mixed-citation>
    </ref>
    <ref id="b48">
      <mixed-citation publication-type="journal"><name><surname>Orchard</surname><given-names>S.</given-names></name><italic>et al.</italic><article-title>Protein interaction data curation: the International Molecular Exchange
(IMEx) consortium</article-title>. <source>Nat Meth</source><volume>9</volume>, <fpage>345</fpage>–<lpage>350</lpage> (<year>2012</year>).</mixed-citation>
    </ref>
    <ref id="b49">
      <mixed-citation publication-type="journal"><name><surname>Consortium</surname><given-names>T. U.</given-names></name><article-title>UniProt: a hub for protein information</article-title>. <source>Nucl. Acids Res</source>.
<volume>43</volume>, <fpage>D204</fpage>–<lpage>D212</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25348405</pub-id></mixed-citation>
    </ref>
    <ref id="b50">
      <mixed-citation publication-type="journal"><name><surname>Berman</surname><given-names>H.</given-names></name>, <name><surname>Henrick</surname><given-names>K.</given-names></name>, <name><surname>Nakamura</surname><given-names>H.</given-names></name>
&amp; <name><surname>Markley</surname><given-names>J. L.</given-names></name>
<article-title>The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive
of PDB data</article-title>. <source>Nucleic Acids Res.</source>
<volume>35</volume>, <fpage>D301</fpage>–<lpage>D303</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17142228</pub-id></mixed-citation>
    </ref>
    <ref id="b51">
      <mixed-citation publication-type="journal"><name><surname>Ashburner</surname><given-names>M.</given-names></name><italic>et al.</italic><article-title>Gene ontology: tool for the unification of biology. The Gene Ontology
Consortium</article-title>. <source>Nat. Genet.</source><volume>25</volume>, <fpage>25</fpage>–<lpage>29</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10802651</pub-id></mixed-citation>
    </ref>
    <ref id="b52">
      <mixed-citation publication-type="journal"><name><surname>Finn</surname><given-names>R. D.</given-names></name><italic>et al.</italic><article-title>The Pfam protein families database: towards a more sustainable
future</article-title>. <source>Nucl. Acids Res</source>. <volume>44</volume>,
<fpage>D279</fpage>–<lpage>D285</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26673716</pub-id></mixed-citation>
    </ref>
    <ref id="b53">
      <mixed-citation publication-type="journal"><name><surname>Acland</surname><given-names>A.</given-names></name><italic>et al.</italic><article-title>Database resources of the National Center for Biotechnology
Information</article-title>. <source>Nucleic Acids Res</source><volume>42</volume>, <fpage>D7</fpage>–<lpage>D17</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24259429</pub-id></mixed-citation>
    </ref>
    <ref id="b54">
      <mixed-citation publication-type="journal"><name><surname>Ashkenazy</surname><given-names>H.</given-names></name>, <name><surname>Erez</surname><given-names>E.</given-names></name>, <name><surname>Martz</surname><given-names>E.</given-names></name>,
<name><surname>Pupko</surname><given-names>T.</given-names></name> &amp;
<name><surname>Ben-Tal</surname><given-names>N.</given-names></name>
<article-title>ConSurf 2010: calculating evolutionary conservation in sequence and
structure of proteins and nucleic acids</article-title>. <source>Nucleic Acids Res.</source>
<volume>38</volume>, <fpage>W529</fpage>–<lpage>W533</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20478830</pub-id></mixed-citation>
    </ref>
    <ref id="b55">
      <mixed-citation publication-type="journal"><name><surname>Keskin</surname><given-names>O.</given-names></name>, <name><surname>Nussinov</surname><given-names>R.</given-names></name> &amp; <name><surname>Gursoy</surname><given-names>A.</given-names></name>
<article-title>PRISM: protein-protein interaction prediction by structural matching</article-title>.
<source>Methods Mol. Biol.</source>
<volume>484</volume>, <fpage>505</fpage>–<lpage>521</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18592198</pub-id></mixed-citation>
    </ref>
    <ref id="b56">
      <mixed-citation publication-type="journal"><name><surname>Chelliah</surname><given-names>V.</given-names></name>,
<name><surname>Blundell</surname><given-names>T.</given-names></name> &amp;
<name><surname>Mizuguchi</surname><given-names>K.</given-names></name>
<article-title>Functional restraints on the patterns of amino acid substitutions:
application to sequence-structure homology recognition</article-title>.
<source>Proteins</source>
<volume>61</volume>, <fpage>722</fpage>–<lpage>731</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16193489</pub-id></mixed-citation>
    </ref>
    <ref id="b57">
      <mixed-citation publication-type="journal"><name><surname>Dinkel</surname><given-names>H.</given-names></name><italic>et al.</italic><article-title>The eukaryotic linear motif resource ELM: 10 years and counting</article-title>.
<source>Nucleic Acids Res.</source><volume>42</volume>, <fpage>D259</fpage>–<lpage>D266</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24214962</pub-id></mixed-citation>
    </ref>
    <ref id="b58">
      <mixed-citation publication-type="other">Marco Biasini. PV-WebGL-based protein viewer. doi: 10.5281/zenodo.12620
(2014).</mixed-citation>
    </ref>
    <ref id="b59">
      <mixed-citation publication-type="journal"><name><surname>Wheeler</surname><given-names>D. A.</given-names></name> &amp;
<name><surname>Wang</surname><given-names>L.</given-names></name>
<article-title>From human genome to cancer genome: The first decade</article-title>. <source>Genome
Res.</source>
<volume>23</volume>, <fpage>1054</fpage>–<lpage>1062</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23817046</pub-id></mixed-citation>
    </ref>
    <ref id="b60">
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>E.</given-names></name><italic>et al.</italic><article-title>Predictive genomics: A cancer hallmark network framework for predicting
tumor clinical phenotypes using genome sequencing data</article-title>. <source>Seminars
in Cancer Biology</source><volume>30</volume>, <fpage>4</fpage>–<lpage>12</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">24747696</pub-id></mixed-citation>
    </ref>
  </ref-list>
  <fn-group>
    <fn>
      <p><bold>Author Contributions</bold> F.T., G.M. and S.C.E.T. conceived the study and experiments. G.M., F.S., F.Q. and
E.L. curated the data. F.T. and D.P. designed and coded the database infrastructure.
F.T., G.M. and S.C.E.T. wrote the paper. All authors read and approved the final
manuscript.</p>
    </fn>
  </fn-group>
</back>
<floats-group>
  <fig id="f1">
    <label>Figure 1</label>
    <caption>
      <title>Example of a mutation as displayed in VHLdb.</title>
      <p>For each mutation all available details are listed (i.e. coding variant,
effect on protein, type of mutation, pVHL surface involved, solvent
accessibility, phenotype, thermodynamic predictions and reference) and
visualized as a red sphere on the surface-colored pVHL structure.</p>
    </caption>
    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep31128-f1"/>
  </fig>
  <fig id="f2">
    <label>Figure 2</label>
    <caption>
      <title>VHLdb home page and VHLdb manually curated interactors set.</title>
      <p>(<bold>A</bold>) VHLdb home page. On the left, a column with version, statistics
and useful links. On the right, a clickable image which redirects to the
pVHL interacting proteins page. (<bold>B</bold>) Manually curated pVHL interacting
proteins sorted by interacting surface. Proteins labelled with modification
are the ones which bind pVHL upon post-translational modification. Proteins
for which no interacting surface could be determined are labeled
unknown.</p>
    </caption>
    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep31128-f2"/>
  </fig>
  <fig id="f3">
    <label>Figure 3</label>
    <caption>
      <title>Example of manually curated interaction annotation.</title>
      <p>For each of the manually curated pVHL interacting proteins, informations from
the manual curation process are listed and, if the pVHL interacting residues
are known, displayed in an interactive window.</p>
    </caption>
    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep31128-f3"/>
  </fig>
  <fig id="f4">
    <label>Figure 4</label>
    <caption>
      <title>Schematic representation of the VHLdb implementation schema.</title>
      <p>Black arrows represent the data flow from curators to end users. The gray
arrow represents the feedback function VHLdb offers to the end users to
report an entry, submit new data o more simply contact the curators.</p>
    </caption>
    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep31128-f4"/>
  </fig>
  <table-wrap position="float" id="t1">
    <label>Table 1</label>
    <caption>
      <title>Example of mutation data contained in VHLdb. For each mutation, codon, effect
on protein, NeEMO prediction, disease and Pubmed id is given.</title>
    </caption>
    <table frame="hsides" rules="groups" border="1">
      <colgroup>
        <col align="left"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
      </colgroup>
      <thead valign="bottom">
        <tr>
          <th align="left" valign="top" charoff="50">Codon</th>
          <th align="center" valign="top" charoff="50">Effect</th>
          <th align="center" valign="top" charoff="50">Surface</th>
          <th align="center" valign="top" charoff="50">NeEMO (Kcal/mol)</th>
          <th align="center" valign="top" charoff="50">Disease</th>
          <th align="center" valign="top" charoff="50">PubMed ID</th>
          <th align="center" valign="top" charoff="50">Curator</th>
        </tr>
      </thead>
      <tbody valign="top">
        <tr>
          <td align="left" valign="top" charoff="50">12</td>
          <td align="center" valign="top" charoff="50">p.Glu12Asp</td>
          <td align="center" valign="top" charoff="50">D</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">HB</td>
          <td align="center" valign="top" charoff="50">21463266</td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">59</td>
          <td align="center" valign="top" charoff="50">p.Pro59Ser</td>
          <td align="center" valign="top" charoff="50">D</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">PH</td>
          <td align="center" valign="top" charoff="50">21463266</td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">66</td>
          <td align="center" valign="top" charoff="50">p.Val66Gly</td>
          <td align="center" valign="top" charoff="50">B</td>
          <td align="center" valign="top" charoff="50">0.17</td>
          <td align="center" valign="top" charoff="50">CNS HB, PC, PH</td>
          <td align="center" valign="top" charoff="50">21463266</td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">103</td>
          <td align="center" valign="top" charoff="50">p.Pro103Ala</td>
          <td align="center" valign="top" charoff="50">B</td>
          <td align="center" valign="top" charoff="50">0.8</td>
          <td align="center" valign="top" charoff="50">PH</td>
          <td align="center" valign="top" charoff="50">21463266</td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">138</td>
          <td align="center" valign="top" charoff="50">p.Pro138Thr</td>
          <td align="center" valign="top" charoff="50">C</td>
          <td align="center" valign="top" charoff="50">1.32</td>
          <td align="center" valign="top" charoff="50">RHB, PH</td>
          <td align="center" valign="top" charoff="50">21463266</td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">155</td>
          <td align="center" valign="top" charoff="50">p.Val155Gly</td>
          <td align="center" valign="top" charoff="50">A</td>
          <td align="center" valign="top" charoff="50">0.19</td>
          <td align="center" valign="top" charoff="50">RHB, RCC</td>
          <td align="center" valign="top" charoff="50">21463266</td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">167</td>
          <td align="center" valign="top" charoff="50">p.Arg167Leu</td>
          <td align="center" valign="top" charoff="50">A</td>
          <td align="center" valign="top" charoff="50">0.02</td>
          <td align="center" valign="top" charoff="50">CNS HB, RHB, PH</td>
          <td align="center" valign="top" charoff="50">21463266</td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
      </tbody>
    </table>
    <table-wrap-foot>
      <fn id="t1-fn1">
        <p>Curator name is reported in the last column. Abbreviations
for the disease column: HB, hemangioblastoma, PH,
pheochromocytoma, CNS HB, central nervous system
hemangioblastoma, PC, prostate cancer, PH, pheochromocytoma,
RHB, retinal hemangioblastoma, RCC, renal cell cancer.
Abbreviations for the curator column: E. L., E.
Leonardi.</p>
      </fn>
    </table-wrap-foot>
  </table-wrap>
  <table-wrap position="float" id="t2">
    <label>Table 2</label>
    <caption>
      <title>Example of manually curated interactors.</title>
    </caption>
    <table frame="hsides" rules="groups" border="1">
      <colgroup>
        <col align="left"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
      </colgroup>
      <thead valign="bottom">
        <tr>
          <th align="left" valign="top" charoff="50">Uniprot ID</th>
          <th align="center" valign="top" charoff="50">Gene Name</th>
          <th align="center" valign="top" charoff="50">pVHL Surface</th>
          <th align="center" valign="top" charoff="50">pVHL interacting residues</th>
          <th align="center" valign="top" charoff="50">Interacting protein residues or domain</th>
          <th align="center" valign="top" charoff="50">Associated disease</th>
          <th align="center" valign="top" charoff="50">Curator</th>
        </tr>
      </thead>
      <tbody valign="top">
        <tr>
          <td align="left" valign="top" charoff="50">P45973</td>
          <td align="center" valign="top" charoff="50">CBX5</td>
          <td align="center" valign="top" charoff="50">B</td>
          <td align="center" valign="top" charoff="50">PXVXL motif, β-domain</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">RCC, PH, HB</td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">P42771</td>
          <td align="center" valign="top" charoff="50">CDKN2A</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">N-terminal Domain</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Q6N084</td>
          <td align="center" valign="top" charoff="50">DKFZp686L11144</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">RCC</td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">P02751</td>
          <td align="center" valign="top" charoff="50">FN1</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">P49841</td>
          <td align="center" valign="top" charoff="50">GSK3B</td>
          <td align="center" valign="top" charoff="50">Modification</td>
          <td align="center" valign="top" charoff="50">Ser68</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Q13547</td>
          <td align="center" valign="top" charoff="50">HDAC1</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">RCC</td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Q92769</td>
          <td align="center" valign="top" charoff="50">HDAC2</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">Disordered</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">P14866</td>
          <td align="center" valign="top" charoff="50">HNRNPL</td>
          <td align="center" valign="top" charoff="50">C</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Q02363</td>
          <td align="center" valign="top" charoff="50">ID2</td>
          <td align="center" valign="top" charoff="50">A</td>
          <td align="center" valign="top" charoff="50">154–174</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">F.Q., G.M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Q92845</td>
          <td align="center" valign="top" charoff="50">KIFAP3</td>
          <td align="center" valign="top" charoff="50">D</td>
          <td align="center" valign="top" charoff="50">1–54</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">O43474</td>
          <td align="center" valign="top" charoff="50">KLF4</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">61–108</td>
          <td align="center" valign="top" charoff="50">CCC</td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">P33993</td>
          <td align="center" valign="top" charoff="50">MCM7</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Q9BQG0</td>
          <td align="center" valign="top" charoff="50">MYBBP1A</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">Pro693</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Q8TEW0</td>
          <td align="center" valign="top" charoff="50">PARD3</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">RCC</td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Q8N2W9</td>
          <td align="center" valign="top" charoff="50">PIAS4</td>
          <td align="center" valign="top" charoff="50">B1/B2</td>
          <td align="center" valign="top" charoff="50">54–120, β-domain</td>
          <td align="center" valign="top" charoff="50">Carboxyl 46 amino acids</td>
          <td align="center" valign="top" charoff="50">RCC</td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">A2A3R6</td>
          <td align="center" valign="top" charoff="50">RPS6</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">P61758</td>
          <td align="center" valign="top" charoff="50">VBP1</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">87–213</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">E. L.</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">O14709</td>
          <td align="center" valign="top" charoff="50">ZNF197</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">55–214</td>
          <td align="center" valign="top" charoff="50">KRAB-A domain</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">F. S., G. M.</td>
        </tr>
      </tbody>
    </table>
    <table-wrap-foot>
      <fn id="t2-fn1">
        <p>For each pVHL-interacting protein, Uniprot ID, Hugo name,
interaction details, disease associated with interaction
disruption, curators and their affiliation are reported.
List of abbreviations for the disease column: CC, colorectal
cancer, RCC, renal cell carcinoma. List of abbreviations for
the curators column: F.S., F. Sundus, F.Q., F. Quaglia,
G.M., G. Minervini, E. L., E. Leonardi.</p>
      </fn>
    </table-wrap-foot>
  </table-wrap>
  <table-wrap position="float" id="t3">
    <label>Table 3</label>
    <caption>
      <title>Distribution of VHLdb interactors and mutations by pVHL interacting
surface.</title>
    </caption>
    <table frame="hsides" rules="groups" border="1">
      <colgroup>
        <col align="left"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
        <col align="center"/>
      </colgroup>
      <thead valign="bottom">
        <tr>
          <th align="left" valign="top" charoff="50">Surface</th>
          <th align="center" valign="top" charoff="50">Start</th>
          <th align="center" valign="top" charoff="50">End</th>
          <th align="center" valign="top" charoff="50">Interactors</th>
          <th align="center" valign="top" charoff="50">Mutations</th>
        </tr>
      </thead>
      <tbody valign="top">
        <tr>
          <td align="left" valign="top" charoff="50">A</td>
          <td align="center" valign="top" charoff="50">T154</td>
          <td align="center" valign="top" charoff="50">D189</td>
          <td align="center" valign="top" charoff="50">9</td>
          <td align="center" valign="top" charoff="50">190</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">B</td>
          <td align="center" valign="top" charoff="50">P60</td>
          <td align="center" valign="top" charoff="50">R109</td>
          <td align="center" valign="top" charoff="50">41</td>
          <td align="center" valign="top" charoff="50">254</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">C</td>
          <td align="center" valign="top" charoff="50">P104</td>
          <td align="center" valign="top" charoff="50">I153</td>
          <td align="center" valign="top" charoff="50">6</td>
          <td align="center" valign="top" charoff="50">284</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">D</td>
          <td align="center" valign="top" charoff="50">M1</td>
          <td align="center" valign="top" charoff="50">R59</td>
          <td align="center" valign="top" charoff="50">1</td>
          <td align="center" valign="top" charoff="50">99</td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Unknown</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">55</td>
          <td align="center" valign="top" charoff="50">280</td>
        </tr>
        <tr>
          <td colspan="3" align="left" valign="top" charoff="50">Upon modification</td>
          <td align="center" valign="top" charoff="50">5</td>
          <td align="center" valign="top" charoff="50"> </td>
        </tr>
        <tr>
          <td align="left" valign="top" charoff="50">Total</td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50"> </td>
          <td align="center" valign="top" charoff="50">117</td>
          <td align="center" valign="top" charoff="50">1074</td>
        </tr>
      </tbody>
    </table>
    <table-wrap-foot>
      <fn id="t3-fn1">
        <p>For each surface, start and end residues as well as the
number of interactors and mutations are reported. The
“upon modification’’ row
indicates the number of proteins which bind the pVHL protein
after it has been phoshorylated in some residue.</p>
      </fn>
    </table-wrap-foot>
  </table-wrap>
</floats-group>
